Mitomycin C market, Mitomycin C is an antibiotic which acts as a doublestranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NADPH:quinone oxidoreductase DTdiaphorase or NADH cytochrome c reductase Mao et al.; Cummings et al..
In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with an average growth rate of 4.76%. In 2016, Global Revenue of Mitomycin C is nearly 119.83 M USD; the actual production is about 17370 K Unit.
The global average price of Mitomycin C is in the increasing trend, from 6.30 USD/Unit in 2012 to 6.90 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Mitomycin C includes 2 Mg, 10 Mg, 40 Mg, and others. The proportion of 2 Mg in 2016 is about 41.5%, and the proportion is in decreasing trend from 2012 to 2016.
Mitomycin C is widely used in Cancer Treatment, Ophthalmic Use, and other field. The most proportion of Mitomycin C is Cancer Treatment, and the proportion in 2016 is 69%. The trend of Cancer Treatment is decreasing.
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016.
North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%.
Market competition is not intense. Kyowakirin, Intas Pharmaceuticals, Teva, BristolMyers Squibb, Aspen, Speciality European Pharma, etc. are the leaders of the industry.
Over the next five years, LPILP Information projects that Mitomycin C will register a 2.3% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 120 million in 2017.
This report studies the global market, especially in North America, Europe, AsiaPacific, South America, Middle East and Africa, focuses on the top 5 players in each region, with sales, price, revenue and market share from 2013 to 2018, the top players:
Kyowakirin
Intas Pharmaceuticals
Teva
BristolMyers Squibb
Aspen
Speciality European Pharma
Alkem Laboratories
Varifarma
APOGEPHA
Market Segment by Regions, this report splits Global into several key Regions, with sales, revenue, market share of top players in these regions, from 2013 to 2018 forecast, like
North America United States, Canada and Mexico
AsiaPacific China, Japan, Southeast Asia, India and Korea
Europe Germany, UK, France, Italy and Russia etc.
South America Brazil, Chile, Peru and Argentina
Middle East and Africa Egypt, South Africa, Saudi Arabia
Split by Product Types, with sales, revenue, price, market share of each type, can be divided into
2 Mg
10 Mg
40 Mg
Other
Split by applications, this report focuses on sales, market share and growth rate in each application, can be divided into
Cancer Treatment
Ophthalmic Use
Others